Analyst Price Targets — ALNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 12:18 pm | — | Canaccord Genuity | $429.00 | $314.40 | TheFly | Alnylam price target raised to $429 from $415 at Canaccord |
| February 13, 2026 3:40 pm | — | Morgan Stanley | $360.00 | $313.75 | TheFly | Alnylam price target lowered to $360 from $408 at Morgan Stanley |
| February 13, 2026 2:23 pm | — | Bernstein | $451.00 | $312.43 | TheFly | Alnylam price target lowered to $451 from $491 at Bernstein |
| February 13, 2026 9:29 am | — | Chardan Capital | $425.00 | $308.48 | TheFly | Alnylam price target lowered to $425 from $475 at Chardan |
| February 12, 2026 6:14 pm | Paul Matteis | Stifel Nicolaus | $444.00 | $313.05 | TheFly | Alnylam price target lowered to $444 from $508 at Stifel |
| January 30, 2026 11:04 am | — | H.C. Wainwright | $510.00 | $346.79 | TheFly | Alnylam price target lowered to $510 from $570 at H.C. Wainwright |
| January 20, 2026 12:47 pm | — | RBC Capital | $465.00 | $359.00 | TheFly | Alnylam price target lowered to $465 from $500 at RBC Capital |
| January 20, 2026 11:04 am | — | Wells Fargo | $376.00 | $359.00 | TheFly | Alnylam price target lowered to $376 from $479 at Wells Fargo |
| January 12, 2026 12:41 pm | — | Needham | $529.00 | $398.29 | TheFly | Alnylam price target raised to $529 from $520 at Needham |
| January 12, 2026 9:48 am | Martin Auster | Raymond James | $472.00 | $398.29 | StreetInsider | Raymond James Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) |
Latest News for ALNY
Elo Mutual Pension Insurance Co lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 26.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,865 shares of the biopharmaceutical company's stock after purchasing an additional 3,738 shares
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Andra AP fonden raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 200.0% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 20,700 shares of the biopharmaceutical company's stock after purchasing an additional 13,800 shares during the period. Andra AP fonden's holdings in
GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 9:10 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALNY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.